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1. Introduction 
Heart failure constitutes a major health problem with a current prevalence of over 5.8 
million in the USA and over 23 million worldwide. (Lloyd-Jones, 2010) During the last 
decades a dramatic increase in the number of heart failure patients and hospitalizations was 
observed (Curtis et al., 2008) with an incidence of more than 550,000 annually in the USA 
and a lifetime risk of 20%. Although prevalence increases with age, heart failure can also 
affect young patients (Lloyd-Jones, 2010; Levy et al, 2002; Lloyd-Jones  et al, 2002). It is also 
estimated that 10% from all HF patients have reached advanced stages of the disease, which 
is characterized by development of symptoms refractory to standard treatment, often 
requiring prolonged hospitalizations, intravenous vasoactive medication and diuretics and 
ultimately, consideration of mechanical support (Ammar et al., 2007). 
Despite the therapeutic advances in the recent decades and the improvement in prognosis 
(drugs that counteract neurohormonal activation, devices that prevent or treat lethal 
arrhythmias and correct dyssynchrony), advanced heart failure remains a lethal clinical 
syndrome. Mortality rate for patients who had to be hospitalized due to heart failure 
deterioration is approaching 75% at 5 years; for end stage patients it is almost 80% (Ammar 
et al., 2007). 
Cardiac transplantation is currently the best available treatment of advanced heart failure, 
but it is available to fewer than 2500 patients in the United States each year, when 
approximately 5–10 people are on the waiting list for each transplant taking place (Taylor et 
al., 2009). In addition, hundreds of thousands of patients who have severe end-stage heart 
failure are not eligible for a heart transplant due to concomitant multisystem disease, 
uncontrolled diabetes, continued tobacco use, or psychosocial limitations; however their 
condition continuously deteriorates. 
The limitations of medical therapy in advanced stage heart failure, the lack of donor organ 
availability, and the large number of patients who do not qualify for transplantation due to 
contraindications,  have spurred interest in mechanical circulatory support (MCS). Since the 
mid 1980s, for patients experiencing recurrent hospitalizations for heart failure 
decompensation despite optimal treatment and manifesting symptoms or signs of 
progressive end organ dysfunction, mechanical support of the circulation with Ventricular 
Assist Devices (VADs) has a well established and continuously expanding role (Stevenson & 
Rose, 2003). In addition to short term support of critically ill patients with appropriate 
devices, long term Left Ventricular Assist Devices (LVADs) have been approved for 
transplant candidates as bridge to transplantation or for patients suitable for destination 
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therapy as permanent treatment (Miller et al., 2007; Slaughter et al., 2009). There is now 
compelling evidence that prolonged unloading of the left ventricle with the use of an LVAD 
is associated with structural reverse remodeling (Mancini et al., 1998; Drakos et al., 2007) 
that can be accompanied by significant functional improvement (Dandel et al., 2005). 
Therefore, a new, although relatively rare indication for mechanical support is emerging, 
namely bridge to recovery (Hon & Yacoub, 2003).  
However, before the use of ventricular assist devices as a “bridge to myocardial 
improvement” or complete recovery becomes feasible, reliable methods to detect complete 
recovery need to be developed. The optimal time for device removal in these cases need also 
to be determined, in order to guarantee safe and effective weaning from the device and 
long-term clinical stability without mechanical support. These tasks are by no means trivial, 
since the operation of the assist device makes evaluation of most of the currently available 
indices (echocardiographic parameters, biomarkers) difficult. 
In addition, the continuously expanding role of LVADs as destination therapy mandates the 
evaluation of device and cardiac function at regular intervals, in order to detect system 
malfunction, thrombosis, or complications such as progression of valvular or right heart 
disease. Changes in patient symptoms or hemodynamics should prompt a thorough 
investigation of the function of both the pump and the supported heart. Knowledge of the 
underlying functional reserve of the patient’s heart is necessary, in order to estimate the 
urgency of a device exchange procedure, in case of mechanical failure. 
For these reasons, evaluation of cardiac function during mechanical support has emerged as 
one of the key factors for the optimal management of this group of patients. Many different 
approaches, involving both established clinical modalities such as echocardiography 
together with advanced techniques at the cellular and molecular level are being applied. 
2. Remodeling: Potentially reversible alterations 
It is important to recognize that HF is a syndrome rather than a primary diagnosis with 
many potential etiologies, diverse clinical features, and numerous clinical subsets. It is a 
progressive disorder with principal manifestation a change in the geometry and structure of 
the LV; the chamber dilates and/or hypertrophies and becomes more spherical—a process 
referred to as cardiac remodeling. Apart from the anatomic changes, the biology of the 
cardiac myocyte, and the structure and volume of myocyte and nonmyocyte components of 
the myocardium, are also affected. 
There are two major categories of unfavorable alterations that occur in failing myocardium; 
these that occur in the volume and structure of cardiac myocytes and these that occur in the 
volume and composition of the extracellular matrix. As far as the first is concerned, 
increasing evidence suggests that progressive myocyte loss, through both necrotic and 
apoptotic cell death due to excessive adrenergic stimulation, (Josue et al., 1907) takes place 
in the myocardium of patients with advanced heart failure (Mann et al., 1992). The loss of 
functional myocardial tissue increases the work of the normal myocardial cells, leading to 
hypertrophy in an attempt to cope with the higher load, by increasing the number of 
sarcomeres. However, the chronically increased rate of energy consumption puts the cells of 
the hypertrophied and failing heart in an energy-starved state (Katz, 1988). Endomyocardial 
biopsies taken from the hearts of patients with congestive heart failure have shown a 
correlation between decreased ATP content and impaired contraction and relaxation. 
(Bashore et al., 1987). Abnormalities in calcium homeostasis were also found in failing 
cardiomyocytes leading to abnormal contractile function and force-frequency relationships. 
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In addition, there are several important changes that occur within the extracellular matrix of 
the myocardium (Thomas et al., 1998; Tyagi et al., 1996; Tyagi et al., 1996; Li et al., 1998), with 
fibrosis being the most widely recognized. Fibrosis due to excessive deposition of fibrillar 
collagen occurs around intramyocardial blood vessels and as replacement of lost myocytes. A 
family of collagenolytic enzymes, matrix metalloproteinases (MMPs), becomes also activated 
within the failing myocardium (Thomas et al., 1998; Tyagi et al., 1996; Li et al., 1998). 
Activation of MMPs leads to progressive degradation of the extracellular matrix, which in turn 
leads to realignment (slippage) of myocyte bundles and/or individual myocytes within the LV 
wall, and thus accounts for the LV wall thinning and the dilation that occurs in heart failure. 
These alterations in the biochemical composition of the myocardium impose several de novo 
mechanical burdens on the failing heart. Perhaps the most obvious problem that occurs in 
the remodeled ventricle is the increase in LV end-diastolic volume, and hence end-diastolic 
wall stress. As the load on the ventricle at end-diastole contributes importantly to the 
afterload of the ventricle at the onset of systole, LV dilation by itself will increase the work 
of the ventricle, and hence the oxygen demand. The increase in wall thinning along with the 
increase in afterload created by LV dilation leads to a functional afterload mismatch that 
may further contribute to a decrease in forward cardiac output and shifts the end-diastolic 
pressure-volume relation (EDPVR) towards larger volumes (Burkhoff et al.; 1988) Moreover, 
the high end-diastolic wall stress may even lead to episodic hypoperfusion of the 
subendocardium with resultant worsening of LV function (Vatner et al., 1988, Shannon et 
al., 1993; LeGrice et al., 1995; Givertz et al., 1998). 
Accordingly, there has been significant interest in developing therapeutic interventions to 
prevent and reverse these processes of adverse remodeling. Both angiotensin-converting 
enzyme inhibitors and nitroglycerin have been shown to attenuate ventricular enlargement 
after myocardial infarction, suggesting, at least in part, that reduction of wall stress may be 
an important factor for amelioration of remodeling (Jugdutt et al., 1988; Pfeffer et al., 1988). 
In addition, chronic ß-blocker therapy reduces ventricular mass and normalizes left 
ventricular shape in patients with heart failure (Hall S et al., 1994). Thus, evidence from 
pharmacological interventions that target neurohormonal activation and hemodynamic 
stress in heart failure suggested that the remodeling process may be reversed to some 
degree, although to a limited extent; this knowledge challenged the notion that ventricular 
dilation due to remodeling in advanced heart failure is an irreversible process. More 
importantly, this generated the hypothesis that ventricular assist devices, which have been 
used in critically ill patients awaiting heart transplantation, may reverse the remodeling 
changes to a greater extent, even up to the level of complete recovery, since they can provide 
profound hemodynamic unloading of the left ventricle, unparallel to the respective achieved 
by combination of drug treatment.  
3. Principles of LVAD operation 
The Artificial Heart Program of the National Heart, Lung, and Blood Institute, chartered in 
1964, sponsored and initialized the development of mechanical cardiac-support devices 
(Hogness et al., 1991). The first goal was to develop a device for the temporary support of  
a patient with terminal heart failure until a donor organ could be found. This strategy has 
become a daily reality in transplantation centers worldwide since the approval by the Food 
and Drug Administration (FDA) of the pneumatically driven left ventricular assist devices 
as a bridge to transplantation in 1994 and of the self-contained, vented electric devices  
for the same purpose in 1998 (Mancini et al., 1998; McCarthy et al., 1998; DeRose et al., 1997). 
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Candidates for left ventricular or biventricular assist devices were patients eligible for 
transplantation with signs of near circulatory collapse, generalized debilitation, or end-
organ deterioration, in order to improve their eligibility for transplantation and their 
chances for survival. The last decade, pulsatile left ventricular assist devices (LVADs) have 
been replaced by devices which continuously expel blood volume from within the failing 
left ventricle into the aorta. In 2008, the Food and Drug Administration approved the use of 
the continuous flow LVAD (HeartMate II) in patients who were candidates for bridge to 
transplantation and in 2010 for destination therapy (Thoratec, 2009). 
4. Types of LVADs 
The first LVADs were pulsatile volume displacement pumps. The main ones are the 
Heartmate I, the Thoratec paracorporeal VAD (PVAD, that can be used to support both 
ventricles), the Berlin Heart (paracorporeal, suitable for biventricular support), Novacor and 
the Cardiowest total artificial heart.  
The Heartmate I has been widely used and inserted in over 5000 patients. It's flow pattern is 
pulsatile, similar to the normal circulation and can pump 4–10 l/min. Valves in the inflow 
and outflow cannulas ensure unidirectional flow through the system. A unique inner 
surface texture negates the use of anticoagulation and only antiplatelet therapy is needed. 
This device was used in the landmark REMATCH trial and was the first one to be approved 
as destination therapy. 
Although pulsatile pumps provide excellent hemodynamic support, they have limitations, 
particularly their large size (hence needing extensive surgical dissection and patients with 
adequate body size), noisy operation, and importantly, limited long-term durability 
(Lahpor, 2009).  
Continuous flow or second-generation axial flow pumps are being increasingly used during 
the last decade, as LVADs. These are continuous-flow rotary pumps that have only one 
moving part, the rotor, unlike the first-generation devices, and hence are expected to be 
more durable. The more frequently used ones are the Heartmate II, Berlin Heart Incor, the 
Jarvik 2000 and the MicroMed-DeBakey VAD. 
The HeartMate II pump (Thoratec Corp.) is the only continuous-flow pump currently 
approved as a bridge to transplantation and destination therapy. This device can be 
operated at a pump speed between 8,000 to 12,000 revolutions/min (RPM), generating flow 
rates up to 10 l/min. In comparison to the first-generation Heartmate I device, it is one-
seventh its size and one-quarter its weight. Over 3000 patients have had a Heartmate II 
implanted and is the most widely used second-generation device. 
The mean duration of support reported for these continuous flow, rotary pumps is longer 
compared with the first-generation devices (166–236 vs. 50–60 days) (El-Banayosy et al., 
2000). The incidence of thrombo-embolic events in HeartMate II patients is in most studies 
comparable with the Heart- Mate I with annual ischemic stroke rates ranging from 3 to 6% 
and for transient ischemic attacks from 1 to 4% (Strüber et al., 2008). Hemorrhagic stroke 
rates tend to be higher (2–3%), probably due to the need for anticoagulation. A somewhat 
higher neurologic complication rate has been reported with the use of another nonpulsatile 
device, the Micromed DeBakey VAD (stroke rate 15–18%). 
Newer implantable (nonpulsatile with magnetic bearings) pumps, such as the VentrAssist, 
DuraHeart and HeartWare, currently under evaluation in clinical trials, may combine the 
advantages of even smaller size with longer durabilty. 
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5. Alteration of cardiac hemodynamics by LVAD support 
The primary action of an LVAD is to provide volume and pressure unloading of the LV, 
while simultaneously restoring systemic blood pressure and blood flow to the peripheral 
organs. At the same time, LVAD support eliminates the need for administration of 
potentially toxic pressors and inotropes (McCarthy et al., 1995; Frazier et al., 1996). With 
most LVADs , this is achieved by withdrawing blood from the left ventricle (most often) or 
left atrium and returning it to the arterial system, providing in this way profound LV 
pressure and volume unloading. This also results in reductions in pulmonary venous and 
arterial pressures and pulmonary vascular resistance (Klotz et al., 2004). The normalization 
of blood pressure and cardiac output, improves perfusion to all body organs, which results 
in improved autonomic function and normalization of the neurohormonal and cytokine 
milieu that is present in heart failure (McCarthy et al., 1995). 
Heart failure is considered a systemic disease that affects many organs because of 
hypoperfusion and the abnormal neurohormonal and cytokine stimulation; normalization of 
the latter by LVADs promotes recovery not only of the heart but of all peripheral organs as 
well (Levine & Levine , 1990). Not all effects of LVAD support, however, are beneficial. 
LVADs provide pressure and volume unloading only to the LV. In the face of increased 
cardiac output, the right ventricle (RV) (often diseased due to a cardiomyopathy process or 
due to chronic pressure and volume overload) can become volume overloaded and unable 
to accommodate the resultant flow (Ochiai et al., 2002). In addition, excessive unloading of 
the LV provokes RV dysfunction, by shifting the interventricular septum to the left. This 
increases RV diameter, right ventricular wall stress and consequently RV afterload. As a 
result, RV distention and failure occur in as many as 20% to 30% of LVAD recipients (Ochiai 
et al., 2002).  More specifically, RV and LV are connected in series and interact with each 
other hemodynamically, due to the anatomic coupling provided by the shared 
interventricular septum and common muscle fibers. The impact of LV support by an LVAD 
on RV geometry, hemodynamics and function can be complex. The reduction of LV filling 
pressures by the LVAD can decrease substantially RV afterload and in that way improve RV 
function. On the same time, the LVAD can increase venous return to the RV (by increasing 
cardiac output), therefore RV operates with a higher preload. An LVAD that excessively 
unloads the LV can produce a leftward septal shift. This can potentially improve RV filling, 
however at the same time it reduces substantially the systolic LV contribution to RV 
contraction, through dyscoordination of interventricular septal motion, and the overall 
effect may be a significant deterioration of RV function. RV failure occurring after LVAD 
implantation can be treated with inotropic agents and pulmonary vasodilators, while at the 
same time optimization of the LVAD function (adjustment of RPM in case of continuous 
flow devices) is mandatory. Despite these measures, simultaneous right ventricular support 
is required in many cases. 
During the previous decade, pulsatile LVADs were dominating clinical use; however, in the 
recent years nonpulsatile devices are by far more frequently used in the clinical practice, and 
next-generation devices in development are also based on the same principal of continuous 
flow (axial or centrifugal). Although these novel devices are, as already mentioned,  smaller, 
more durable and reliable, more energy efficient, less thrombogenic, and less surgically 
traumatic to implant, they do not generate normal pulsatile flow. Although there is 
considerable data that long term non-pulsatile flow does not have detrimental effects on 
end-organ function, little is known about the consequences of lack of pulsatility on reverse 
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remodeling. Klotz et al investigated the hemodynamic effects during long-term support 
with nonpulsatile and pulsatile LVADs; they found that LV pressure unloading was similar 
between these 2 types of LVADs, whereas LV volume unloading was significantly more 
pronounced with a pulsatile device (Klotz et al., 2004). The significance of this difference is 
not known.  
Thohan et al showed that although there are differences between these two classes of 
devices with regard to magnitude of unloading, both forms of support were equally 
effective in normalizing cell size and tumor necrosis factor-alfa levels (Thohan et al., 
2005). 
Most recently, Bartoli et al studied the effect of continuous vs pulsatile devices on cardiac 
hemodynamics, in a bovine model of left ventricular heart failure. Their data revealed that 
continuous unloading diminished energy requirements during cardiac cycle to non-
physiological levels, particularly at higher levels of support. During increasing levels of 
continuous unloading, the variation between end-systolic and end-diastolic pressures 
diminished significantly, volumes and pressures decreased to non-physiologically low 
values and resulted in chronic closure of the aortic valve. On the other hand, pulsatile flow 
during left ventricular support, despite similar reduction in left ventricular end diastolic 
volumes, preserved a normal range of physiologic pressures. Therefore, continuous unloading 
dramatically reduces cardiac metabolic demands to values that are not normally observed in 
mammals; the significance of this observation for cardiac function during long term support 
is still unknown (Bartoli et al., 2010). 
However, there are also physiological limitations to the function of pulsatile VADs. Klotz et 
al. demonstrated that with pulsatile LVADs device ejection is not generally coordinated 
with ventricular contraction and this device–heart dyssynchrony may paradoxically increase 
afterload. This is a result of the fact that native left ventricular contraction can occur at a 
phase when both the inlet valve of the device and the native aortic valve are closed (the 
latter due to higher aortic than ventricular pressure). This results in isometric ventricular 
contraction, which is energy demanding and non-efficient and can cause excessive 
stretching of the myocardium, particularly in the presence of systemic hypertension, which 
can occur following left ventricular assist device insertion, particularly of the pulsatile type. 
Regurgitation of the inlet valve of the left ventricular assist device can also result in systolic 
and diastolic stretching of the myocardium. On the other hand continuous-type flow 
pumps, are not subject to such dyssynchrony. While the degree of pressure unloading is 
similar to pulsatile LVADs, systemic arterial pressure is not increased to the same extent 
with continuous flow LVADs. In addition, although flow across the aortic valve is evident in 
less than 40% of the patients with continuous flow LVADs, as already mentioned, the 
absence of inflow and outflow device valves allows forward flow during each left 
ventricular ejection, even if this occurs with low systolic pressures. In that way, the afterload 
of the native ventricle is kept low continuously.  
These fundamental, functional differences between the pulsatile and nonpulsatile LVADs 
are crucial especially for the evaluation of cardiac function after device implantation, as it 
will be later shown. 
6. Reverse remodeling 
One of the earliest recognized changes of patients’ hearts supported by an LVAD until 
transplantation was the reduction of the size of the cardiac silhouette on chest radiographs, 
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observed immediately before transplantation possibly due to the unloading of the dilated 
heart. In addition, retrospective analysis of echocardiograms showed that after a short term 
period of LVAD support, LV end diastolic diameter decreased significantly (6.81 to 
5.39mm), with corresponding increases in ejection fraction (11% to 22%). Echocardiographic 
studies performed in the pre-implant period and at explantation at the time of transplantation 
in 20 patients, in order to further investigate the effect of unloading on left ventricular 
function, showed a significant decrease in LV end-diastolic volume, LV end-systolic volume, 
left atrial volume, and an increase in LV ejection fraction (Thohan et al., 2005).  
LV pressure-volume relationships were also evaluated in LVAD supported hearts after 
explantation and a shift towards normal was observed, suggesting that multiple favorable 
alterations at the cellular, tissue and whole organ level had occurred, described with the 
general term reverse remodeling (Levin et al., 1995). Although the hearts did not return to 
completely normal size, an average time of 30.8 days was needed in order for the reverse 
remodeling to be observed, while at 90 days most of the process was completed in this 
patient cohort (Madigan et al., 2001). In contrast, reverse remodeling of RV in LVAD 
supported hearts was not observed, suggesting that reverse structural remodeling is 
primarily mediated by the profound hemodynamic unloading and not only by normalized 
neurohormonal milieu, as previously already mentioned (Barbone et al., 2001). Another 
explanation of this discrepancy in favorable outcome between the LV and the RV might be 
the RV dysfunction induced by excessive LV unloading, as previously explained. It is of 
interest that when an RVAD is implanted in the RV, changes in the RV End Diastolic 
Pressure - Volume relationships are comparable with those observed in the LV of LVAD 
supported hearts (Klotz et al., 2005).  
In addition to the effects on structure, the LVAD supported hearts on average exhibited 
reduced left ventricular trabeculae length, diameter, and mass as compared to the medically 
managed hearts. LVAD support, led also to increased contractile strength, faster time to 
peak concentration and reduced time to 50% relaxation in isolated cardiomyocytes (Dipla et 
al., 1998). Myocytes also exhibited improved contractile responses to increased frequency of 
stimulation, an effect blunted in end-stage heart failure. This was paralleled by 
normalization of b-adrenergic receptor density and reversal of RyR2 hyperphosphorylation 
(Marx et al., 2000). In addition, Klotz S et al. showed that LVAD support was associated 
with a significant increase in total and especially cross linked collagen deposition in LV 
myocardium ( Klotz et al., 2005). The levels and activity of matrix metalloproteinases tended 
to decrease following LVAD support. Again, a similar structural reverse remodeling was 
not generally observed in the RV (Barbone et al., 2001).  
7. Bridge to recovery 
Even in the first Bridge to Transplantation trials, a small but increasing number of cases was 
noted where after a certain time of support the ventricular function improved sufficiently to 
allow consideration of removal of the device. Some patients, after explantation, were 
discharged without requiring heart transplantation and the idea of bridge to recovery 
emerged (Levin et al., 1994). In 1996, Levin et al. described for the first time the explantation 
of an LVAD in a 19-year-old man who had advanced heart failure caused by idiopathic 
dilated cardiomyopathy. Following LVAD support for 183 days the device was explanted 
but unfortunately, the heart redilated soon after the explantation procedure; ejection fraction 
worsened, and the patient died of heart failure (Levin et al., 1996).  
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In 1998 Mancini et al published a retrospective review of a total of 111 LVAD patients, 
evaluated for cardiac recovery. Only 5 successful explantations were identified (Mancini et 
al., 1998). 
Low rate of recovery (9%) was published from Maybaum et al. in a study that included 67 
patients supported by LVAD. Simon et al reported recovery in 11% of the non ischemic 
patients and only 2.5% in the ischemic population in a study of 154 LVAD patients (Simon et 
al., 2005). 
However, in other series results have been more promising. In patients with acute myocarditis, 
it is well known that the combination of profound mechanical cardiac unloading and the 
appropriate therapy allows complete recovery and weaning from LVAD support in many 
cases (Farrar et al., 2002; Grinda et al., 2004). Muller et al reported a higher percentage of 
recovery and explantation in 17 patients with dilated cardiomyopathy; In 5 out of the 17 
(29%) patients after 160 days of mechanical support the LVADs were successfully explanted 
and patients maintained normal cardiac function for 51 to 592 days (Muller et al., 1997) 
The most promising results were reported by Yacoub and co-workers, with the use of a 
protocol combining mechanical unloading of the left ventricle with an optimum medical 
treatment at maximal tolerated doses, including β2-receptor stimulation. With this 
approach, in a carefully selected patient population of dilated cardiomyopathy patients, 11 
of 15 (73%) demonstrated cardiac recovery sufficient to undergo successful device 
explantation, with 100% and 89% cumulative rates of freedom from recurrent HF at 1 and 4 
years, respectively (Birks EJ et al., 2006). This study was conducted using the first-
generation, pulsatile HeartMate XVE device. Interestingly, the same group demonstrated 
better results for quality of life in the bridge to recovery group 3.6 years after the LVAD 
removal, compared to the bridge to transplantation patients and even to transplanted 
patients (George et al., 2008). 
Recently, the same investigators presented data supporting the feasibility of sustainable 
myocardial recovery using a continuous flow LVAD. They published the results of 19 non 
ischemic cardiac failure patients, who underwent implantation of a HeartMate II pump as a 
bridge to recovery. The successful explantation rate was 63.2% at 2 years. Estimated survival 
without heart failure recurrence was 83.3% at 1 and 3 years (Birks et al., 2011). 
Nevertheless, results from other, larger series of DCM patients were not similarly 
encouraging, either as far as explantation rates or sustainability of recovery is concerned. All 
these studies should be interpreted with caution, since patient selection, devices and 
pharmacological protocols varied considerably. However, if bridge to recovery ever 
becomes an acceptable indication for LVAD therapy, the need for validated protocols for left 
ventricular function assessment during support will become even more pressing. 
8. Destination therapy 
After the landmark REMATCH trial, LVAD use as destination therapy became an accepted 
indication, for patients with advanced stage heart failure and contraindications to cardiac 
transplantation. Recently, even better results have been achieved with the new generation 
continuous flow pumps. Although destination therapy is considered permanent, there are 
many reasons why assessment of cardiac function should be performed regularly. Right 
ventricular failure can manifest even many years after LVAD implantation. Aortic valve 
disease can also progress after many years of support and can have important 
hemodynamic consequences.  
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9. Evaluation protocols 
Despite these promising results, the clinical reality shows that the actual percentage of true 
complete myocardial recovery leading to successful weaning and device explantation is low. 
Therefore, identification of these patients is a challenging but absolutely necessary task, in 
order to avoid inappropriate device explantations and risking significant patient morbidity 
and mortality.  
Several groups have used protocols to assess functional performance of the native heart, 
under reduced levels of support.  
Mancini et al. attempted to define criteria in order to identify potential candidates for LVAD 
explantation. They analyzed a retrospective cohort of 111 LVAD supported patients. They 
were able to find 5 patients that successfully underwent explantation of the LVAD. 
However, in 4 heart failure recurred, 2 died and 2 underwent new LVAD implantation 
(interestingly, in one of them recovery was again observed). Only one patient remained 
clinically stable with good LV function at 15 months after explantation. Subsequently, they 
applied strict criteria in a prospective cohort of 39 patients, supported by the pulsatile 
HeartMAte XVE system. They used cardiopulmonary exercise testing, right heart 
catheterization, echocardiographic, and data from the LVAD sensor. Measurements were 
obtained during stress in the automated mode of the device (full support), during down 
titration of the level of support, and during exercise at a fixed low rate (20bpm). Adequate 
peak VO2 (>20ml/kg/min) and cardiac output (10 l/min), the presence of an open aortic 
valve during each cardiac cycle and maintenance of normal-size left ventricle with normal 
fractional shortening after completion of the exercise protocol at low support levels were 
criteria for LVAD explantation. Significant clinical recovery occurred in only one of the 
prospectively studied patients. Limitations of this protocol were the relatively short period 
of support and the rapid weaning protocol used, that may have not allowed adaptation of 
patient’s hemodynamics and neurohormonal status to the higher demands of the low-
support status (Mancini et al., 1998b).  
Other studies have confirmed the results of low rates of ventricular recovery, as well as the 
recurrence of heart failure frequently with the need of LVAD re-implantation, a process 
often referred to as recurrent remodeling (El-Banayosy et al., 2001; Helman et al., 2000). A 
common finding in these studies was the higher rate of recovery in patients with idiopathic 
dilated cardiomyopathy. 
Muller et al used a more progressive and prolonged weaning procedure in order to identify 
truly recovered patients. They evaluated 17 patients with IDC under support with pulsatile 
pumps (Novacor or HeartMate XVE). They used echocardiography after 4 minutes of 
complete withdrawal of support to assess complete myocardial recovery (stable EF and 
ventricular dimensions at normal or nearly normal levels). Subsequently, they put patients 
with signs of substantial recovery on fixed, asynchronous mode of support for 3 consecutive 
weeks, in order to test the stability of cardiac function. The fixed-rate mode leads to a 
dissociation in the coordination between cardiac ejection and optimum filling of the pump, a 
discrepancy that tends to increase left ventricular afterload. When this occurs, 
synchronization between heart and pump is random at best. Investigators were able to 
identify 5 patients who underwent successful LVAD explantation. All remained clinically 
stable for a period of 51 to 592 days. The approach of keeping patients at increased demands 
(high afterload) before removal is intriguing, because it could potentially identify those at 
risk for rapid deterioration. Unfortunately no data about hemodynamics, echocardiography 
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parameters or exercise tolerance at the completion of this testing period were provided. 
Nevertheless, 29% of the IDC patients were successfully weaned. Importantly, all patients in 
this study were under maximum pharmacological treatment. Another interesting 
observation was that, according to the findings of this study, longer periods of support 
(ventricular unloading for more than 100 days) may have actually been detrimental to 
recovery and may have contributed to myocyte atrophy (Muller et al., 1997). 
Maybaum et al. in a prospective, multicenter, observational study used a slightly different 
clinical protocol for the evaluation of recovery in 67 patients supported by pulsatile pumps. 
Monthly assessments were performed including resting echocardiogram at full and reduced 
(output of 4 l/min) LVAD support, and cardiopulmonary exercise testing in ambulatory 
patients. Patients with LV ejection fraction (LVEF) 40% at reduced device support 
underwent dobutamine echocardiography with simultaneous hemodynamic monitoring. 
Complete recovery leading to LVAD explantation was observed only in the 9% (6/67) of the 
patients enrolled. Some interesting observations were made in this study. All patients that 
were successfully weaned demonstrated high contractile reserve on the dobutamine 
echocardiogram (mean EF of 60±10% at peak dobutamine dose), suggesting that contractile 
reserve may be a valid clinical tool for studying LV function under LVAD support. At the 
lowest rate of support, recovered patients had a wedge pressure of 8.5±4.5 versus 15±5.7 
mm Hg of those that did not demonstrate similar improvement, indicating that a normal 
wedge pressure under partial support can be an important indicator of genuine recovery. 
Four out of 6 of the recovered patients had a short history of heart failure (2 acute 
myocarditis, 1 recent myocardial infarction, one IDC of recent onset) and they all remained 
stable post-explantation. The remaining two had chronic IDC and experienced a reduction 
of EF shortly after explantation, without clinical consequences. On the other hand, all 
supported patients improved their exercise tolerance and there was no discrimination of this 
parameter with genuine recovery. It should be noted that exercise tests were performed 
under maximal support. However, improvement of skeletal muscle function may act as a 
confounding factor for interpretation of the results of cardiopulmonary stress test in patients 
with LVADs. 
In 2006, the Harefield group, led by Magdi Yacoub, reported the most intriguing data, as far 
as bridge to recovery protocols are concerned. They proposed and evaluated a combination 
therapy involving LVAD support to achieve maximal unloading of the myocardium, 
together with pharmacological therapy at the maximal tolerated doses, aiming at reversal of 
remodeling, followed by addition of pharmacologic stimulation of the β2 receptors by 
clenbuterol, for the development of physiological hypertrophy of the cardiac muscle. More 
specifically, ACE inhibitors, angiotensin 1 receptor antagonists, spironolactone and beta 
blockers with their well established effect on reverse remodeling were administered to the 
mechanically supported patients. Once maximal reverse remodeling had been achieved, a 
program of inducing physiological hypertrophy was instituted. This consisted of 
administration of the beta-2 agonist clenbuterol which is known to induce skeletal muscle 
hypertrophy (Petrou et al., 1995) and improve performance, as well as to stimulate 
physiological ‘myocardial hypertrophy’ (Wong et al., 1998). Evidence of recovery was 
monitored by repeated echocardiographic measurements and a ‘6 min walk’ test with the 
device (pulsatile HeartMate XVE) switched off (on heparin). Patients also underwent 
cardiopulmonary exercise stress test, right and left heart catheterization (including left and 
right heart pressures, cardiac output with the device on and off, left ventricular angiography 
and left ventricular biopsies). Explantation was considered if the following criteria were met 
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(with the device off for 15 minutes): a) left ventricular end-diastolic diameter < 60 mm;  left 
ventricular end-systolic diameter <50mm; LVEF >45%; left ventricular end-diastolic 
pressure (or pulmonary-capillary wedge pressure) < 12 mm Hg; a resting cardiac index > 2.8 
l/m2; maximal oxygen consumption (VO2 max) with exercise > 16 ml/kg/min and a 
VE/VCO2 slope < 34. Explantation of the device was feasible in 73% of the patients with 
idiopathic dilated cardiomyopathy who could be enrolled in the study (or in 46% of all the 
IDC patients that underwent implantation of an LVAD at this period in their center), with 
100% and 89% cumulative rates of freedom from recurrent HF at 1 and 4 years, respectively 
(Birks et al., 2006). It should be noted that patients who could be weaned from LVAD 
support, not only fulfilled the above mentioned criteria, but achieved values within the 
normal range on these tests: LVEF of 64±8% before explantation (12±6% before implantation, 
P=0.001), left ventricular end-diastolic diameter of 55.9±8.3 mm (compared with 75.1±16.3 
mm, P=0.002), mean left ventricular end-systolic diameter 39.6±6.5 mm (compared with 
66.9±16.3 mm, P=0.002). Before explantation, VO2 max (with the pump off) was 20.7±6.1 
ml/kg/min and VE/VCO2 slope 32.5±7.9. Pulmonary-capillary wedge pressure before 
explantation (with the device off for 15 min) was 9.0±4.1 mm Hg and cardiac index 2.8±0.7 
l/m2. Interestingly, the same group demonstrated better results for quality of life in the 
bridge to recovery group 3.6 years after LVAD removal, compared to bridge to 
transplantation patients and even to transplanted patients (George et al., 2008). These 
impressive data proved that in carefully selected patients, long term, stable myocardial 
recovery can be achieved and this may be a legitimate treatment target for IDC patients 
requiring mechanical support, in order to improve not only their prognosis and quality of 
life but also donor organ allocation, particularly in the era of donor organ shortage. 
However, selecting the appropriate candidates for this treatment remains a formidable task, 
since there are no criteria to predict which patient will experience recovery and if this 
improvement is going to be sustained for a long enough period to justify the risks of 
withdrawing mechanical support. 
Extremely important data became also available from Hetzer’s group in Berlin. They were 
able to wean 24.4% of 131 DCM patients from LVAD support (pulsatile devices in the vast 
majority) (Dandel et al., 2005). They also used off-pump tests in order to obtain 
echocardiographic measurements. An LV diastolic diameter < 55 mm and and LVEF> 45% 
were considered criteria for complete recovery, however they proceeded to device 
explantation in some patients with evidence of partial recovery. When patients were 
considered for device removal, an off-pump right heart catheterization was performed and 
normal right atrial and capillary wedge pressures were mandatory before proceeding to 
explantation. Twenty two / 32 patients experienced clinical stability for at least 3 years, 
whereas in 10 patients heart failure recurred and 8 of them required cardiac transplantation. 
Partial recovery in the echocardiogram as well as a history of IDC for more than five years 
was predictors of heart failure recurrence. 
The same investigators also reported results about long term clinical stability of 35 IDC 
patients successfully weaned from LVAD support (Dandel et al., 2008). Decision for LVAD 
explantation was made based on off-pump echocardiographic assessment. For pulsatile 
devices, a complete cessation of LVAD operation was induced, under full heparinization. 
For continuous flow devices, echocardiography was performed after reduction of pump rate 
(revolutions per minute) at the lowest levels where retrograde flow (from the aorta to the 
LV) through the device was not observed. In addition to the above mentioned criteria, 
geometry of the LV was also assessed and LV relative wall thickness (RWT) >0.30 and 
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sphericity index < 0.8 were considered favorable indices. Recurrence of heart failure was 
observed in 16/35 of the patients and again evidence of partial recovery in the 
echocardiogram as well as a history of heart failure of more than 5 years and a required LV 
support duration of more than 6 months for induction of recovery. 
Recently, the Harefield group, using the same medical treatment protocol published data 
from 19 patients with non ischemic cardiomyopathy, who received a continuous flow LVAD 
(Thoratec HeartMate II) as a bridge to recovery. LV function was monitored with monthly 
postimplantation echocardiographic measurements of the LV diameters and LVEF. As 
already mentioned, no real off-pump test can be performed with continuous flow pumps, 
because cessation of rotor function would result in backflow of blood from the aorta to the 
LV through the device, and therefore it would impose a tremendous volume overload on 
the LV. Therefore, the investigators performed echocardiograms, as well as 6-minute walk 
and cardiopulmonary exercise tests both with the device at optimal speed and after 
reduction of the level of support at 6000 rpm, where no regurgitation would occur. Right 
and left heart cardiac catheterizations were performed before explantation, again with the 
device at optimal speed and at 6000 rpm for at least 15 minutes. Using the same criteria for 
explantation as in their original study, complete recovery that allowed device explantation 
was achieved in 12/19 patients (63.2%), after 286±97 days. Estimated survival without heart 
failure recurrence was 83.3% at 1 and 3 years. Before explantation, at low flow for 15 
minutes, ejection fraction was 70 ± 7%, left ventricular end-diastolic diameter was 48.6 ± 5.7 
mm, left ventricular end-systolic diameter was 32.3 ± 5.7 mm, VO2peak was 21.6 ± 4 
mL/kg/min, pulmonary capillary wedge pressure was 5.9 ± 4.6 mm Hg, and cardiac index 
was 3.6 ± 0.6 L/min/ m², indicating again that complete normalization of LV function and 
hemodynamics is associated with clinical stability and better long term outcome after 
explantation. 
Importantly, this group thoroughly investigated methods to assess cardiac function under 
support with a continuous flow LVAD (Thoratec HeartMate II). They performed 
echocardiography at gradually lower rates of pump rotor speed and confirmed that at a 
fixed rate of 6000rpm, no forward or backward flow through the device could be identified. 
Therefore, pump speed at 6000rpm can induce physiologic loading on the LV and can be 
used for valid off-pump evaluations (George et al 2010). The same investigators also tried to 
clarify the role of optimal pump speed function on cardiopulmonary exercise stress test 
parameters. They were able to demonstrate that a rapid reduction of pump speed from 
optimal to 6000 rpm resulted in a reduction of VO2peak of 23% and of exercise duration of 
18%. Despite the fact that multiple factors can influence exercise tolerance, and therefore a 
single value of VO2peak that can be considered threshold discriminating recovered patients 
probably does not exist, the relative change of this parameter between a test performed at 
optimal pump speed and at 6000 rpm is very important. Although this issue has never been 
addressed directly, ideally for a patient to be considered eligible for device explantation, 
these two values should not be significantly different (Jakovljevic et al., 2010). 
Recently, stress echocardiography has been used in order to establish echocardiographic 
criteria for better evaluation of the native heart. In exercised patients, the systolic mitral 
annular motion increases significantly in parallel with cardiac output and the ratio of peak 
mitral E-wave velocity to early mitral annulus velocity (E/e’), has been demonstrated as a 
good approximation of LV filling pressures during exercise. These two parameters can be 
used as indices of cardiac output and pulmonary pressures in mechanically supported 
patients, even during off-pump tests. 
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In conclusion, although more or less similar methods are being used for LV function 
assessment during LVAD support, by most of the expert groups, criteria to diagnose 
recovery and results concerning the possibility for weaning from mechanical support vary 
considerably. There are no universally accepted patient selection criteria, as well as 
parameters that will safely predict adequate recovery and long term clinical stability after 
device explantation. Currently used criteria by most of the experienced groups for detection 
of recovery, as well as appropriate evaluation tests for pulsatile and non-pulsatile devices 
are summarized in Tables 1, 2 and 3. 
 
 LVEF LVIDd PCWP RAP VO2max 
Dandel  
et al., 2005 
≥45% ≤ 55mm ≤10mmHg ≤8mmHg - 
Maybaum  
et al., 2007 
≥40% - - - - 
Mancini  
et al., 1998 
- ≤ 55mm ≤10mmHg - 20ml/kg/min 
Yacoub  
et al., 2006, 2011 
≥45% ≤ 60mm 
(LVESD<50mm)
≤12mmHg - >16ml/kg/min 
(VE/VCO2slope< 34) 
Muller  
et al., 1997 
≥41% ≤58mm - - - 





echocardiography (LVEF, LVEDD, LVESD, mitral E/A ratio, tricuspid 
regurgitation velocity, pulmonary valve acceleration time) 
doboutamine echocardiography (same parameters as above) 
cardiopulmonary exercise testing ( VO2max, VE/VCO2slope) 
right heart catheterization (PCWP, RAP) 
6 min walking test 





Reduced level of support (revolutions per 
minute: 6000rpm) 
echocardiography (LVEF, LVEDD, LVESD, mitral E/A ratio, tricuspid 
regurgitation velocity, pulmonary valve acceleration time ) 
doboutamine echocardiography (same parameters as above) 
cardiopulmonary exercise testing ( VO2max, VE/VCO2slope) 
right heart catheterization (PCWP, RAP) 
6 min walking test 
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10. Assessment of cardiac function during LVAD support as bridge to 
transplantation or destination therapy 
Although recovery during support with an LVAD is an intriguing concept that merits 
further investigation, in everyday clinical practice, there are several more common reasons 
why native LV function should be monitored, despite the presence of an LVAD. During the 
recent years, data have accumulated about the long term problems that can manifest in 
patients supported by an LVAD, even many years after the implantation. 
10.1 Determine optimal settings of LVAD function 
Currently, continuous flow (axial or centrifugal) pumps are by far the most frequently used 
ones in the clinical practice, for long term patient support. Although maintaining adequate 
cardiac output to preserve end organ function and allow patients to be completely 
asymptomatic in their daily activities is an obvious need, optimal rotor speed of these 
pumps has not been determined yet, and seems to be a highly individualized parameter. For 
this decision, echocardiography provides the most easily accessible and valuable information. 
Many echocardiographic parameters should be taken into account, including LV and RV 
dimensions, the presence of mitral or tricuspid valve insufficiency, the shape of the interatrial 
or interventricular septum. At optimal pump interventricular and interatrial septum are at 
neutral position or slightly shifted to the left, whereas mitral and tricuspid valve regurgitation 
are minimal. Although, it is sometimes difficult to obtain good echocardiographic images in 
these patients, due to the apical cannula that often interferes with image acquisition, 
echocardiography remains the modality of choice for this kind of assessment, since it is 
noninvasive and widely available. 
10.2 Aortic valve function 
As far as the aortic valve is concerned, pulsed-wave Doppler can be used to assess flow 
across this valve. In patients with continuous flow mechanical support, aortic valve closure 
during the entire cardiac cycle has been found in up to 83% of patients, whereas a minority 
has intermittent opening with no detectable flow across the valve (Topilsky et al., 2011). This 
happens because at high pump speeds, the device unloads the LV at a point where LV 
systolic pressure is lower than aortic pressure and thus the aortic valve remains closed. On 
the other hand, with lowering of the revolutions per minute (RPM), the percentage of 
cardiac cycles where opening of the aortic valve occurs increases substantially. A 
continuously closed valve can have leaflet fusion as a consequence. This is commonly 
observed in patients with continuous flow LVADs and can have severe implications. Blood 
stasis and eventually thrombosis increases the risk of thromboembolic events and therefore 
more intense anticoagulation is needed. Aortic insuffiency can also develop or worsen (if 
preexisting) when the valve is constantly closed. The cause of this type of insufficiency is 
multifactorial; loss of pulsatility and chronically elevated aortic root pressure (the smaller 
device outflow diameter requires higher velocities to maintain the appropriate flow) 
produce high radial aortic root sheer stress, valve malcoaptation and finally aortic 
insufficiency. In addition, lack of regular aortic valve opening may independently promote 
valve thickening and fusion. 
Recently it was reported that 6% of the patients with HMI will develop aortic insufficiency 
after a mean duration of 50 days of mechanical support and 11% after 1 year; 14% of the 
patients with HMII after 90 days of mechanical support and 25% after 1 year. This fact 
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points out the importance of pre-operative evaluation of the aortic valve in order to detect 
valve insufficiency and address it surgically during implantation. Moreover, since HMII is 
being increasingly used for destination therapy, it is important to exercise vigorous 
postoperative surveillance of these patients for aortic insufficiency development. In this 
direction frequent evaluation with echocardiography of the aortic root is mandatory, since 
aorta often dilates during mechanical support, especially in HMII patients who have closed 
aortic valves. In patients who can tolerate lower pump speeds without developing symptoms 
or signs of low cardiac output and end organ hypoperfusion, setting device function at a 
level that allows aortic valve opening every 3rd to 5th cardiac circle may ameliorate the 
problem. 
10.3  Right ventricular function  
Monitoring right ventricular function not only before but also after LVAD implantation is 
also crucial. As already mentioned right ventricular failure develops in about 20-30% of the 
patients supported with an LVAD. Under normal conditions, after LVAD implantation, the 
unloading of the LV reduces left atrial and mean pulmonary pressure improving right 
ventricular function. However, abnormal interventricular septum shift towards the left 
during unloading of the LV reduces the efficiency of RV contraction and additionally the 
elevated RV preload can deteriorate even more RV function leading to RV failure, which is 
associated with very high post-LVAD morbidity and mortality rates. RV failure after LVAD 
implantation increases the perioperative mortality rate from 10%–15% for those without RV 
failure to 38%–43% (Matthews et al., 2008). 
Preoperative evaluation of RV and intraoperative and postoperative protection of RV 
function and management of RV failure are beyond the scope of the present manuscript. 
However RV failure may develop even late after LVAD implantation, as a cause of 
chronically increased RV preload (due to the increased cardiac output by the LVAD and 
parallel increased venous return), increased wall stress, changes in geometry of the RV in 
case of excessive leftward shift of the intraventricular septum and progressive tricuspid 
annular dilatation, which results in reduced tricuspid valve coaptation and increased RV 
preload due to tricuspid regurgitation. It must be emphasized that the RV is diseased in 
most of the times (cardiomyopathy, prior right ventricular myocardial infarction) and 
therefore poorly tolerates chronically elevated preload. Periodical echocardiographic 
assessments after LVAD implantation should be performed and if RV failure is detected 
appropriate therapeutic measures should be applied, i.e. reduction of pump speed if 
possible, in order to reduce preload and avoid excessive IVS leftward shift and diuretics to 
decrease RV preload. The role of RV afterload reducing agents, such as sildenafil, that can 
selectively reduce pulmonary vascular resistance, has not been studied in this clinical 
setting, but in theory appears as an attractive option. 
10.4 Mitral valve function 
MV regurgitation is rarely a problem in LVAD patients. LV unloading during LVAD 
support reduces LV size and filling pressures, improves coaptation of the MV leaflets and 
significantly reduces MR. In case mitral regurgitation appears after continuous LVAD 
implantation, inadequate LV decompression should be suspected and the possibility of 
increasing LVAD speed should be considered. Pulsatile LVADs by operating in a full-to-
empty mode reduce the mitral regurgitation more than continuous-flow LVADs. 
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10.5 Assessment of device function-malfunction 
Since device malfunctions may appear at any time after implantation (17% of deaths in 
REMATCH trial), if the patient’s cardiac function is known to be severely compromised, 
emergency device exchange may be required even before symptomatic heart failure 
develops. The most common cause of continuous LVAD dysfunction is impeller thrombosis, 
which leads to reduced LVAD flow, and increased power use by the device. In this case, left 
ventricle is not fully unloaded and the increase in LV end diastolic volume will cause 
significant functional mitral regurgitation, right sift of the interventricular and interatrium 
septum and opening of the aortic valve in every LV contraction. In addition to these 
echocardiographic findings, laboratory analysis in patients with intravascular hemolysis 
will reveal increased LDH, plasma hemoglobin, bilirubin and D-dimers. 
11. Conclusion – Future perspectives 
Although the role of left ventricular assist devices as a bridge to transplantation or 
destination therapy is well established and high success rates have been achieved, the active 
monitoring of these patients for possible recovery is desirable for many reasons. For bridge 
to transplant patients, shortage of donor organs mandates the best allocation possible and 
removal from the list even of a small number of patients would increase the chances for a 
transplant of those who don’t have other options. For patients initially selected for 
destination, recovery and device explantation would relieve them from risks of device 
related morbidity and mortality (device malfunction, thrombosis, bleeding and infection). 
In order to materialize this very ambitious target, several prerequisites need to be satisfied: 
• Criteria for optimal patient selection should be developed. These will rely on accurate 
diagnosis of the underlying disease that led to heart failure as well as disease duration. 
• Optimal pharmacologic management of bridge to recovery patients needs to be 
established. Drug regimen should probably include all the available anti-remodeling 
substances, at maximal tolerated doses, and possibly β2-stimulation, but the efficacy of 
this approach needs to be demonstrated in randomized trials. 
• Reliable protocols for evaluation of cardiac function under mechanical support need to 
be applied. These should be based on some type of off-pump test, depending on device 
type, and involve echocardiography, right heart catheterization and exercise stress test. 
It is not only the presence of good function of the native left ventricle that needs to be 
detected, but also long term stability that needs to be predicted. The latter remains the 
most challenging task currently. More prolonged in duration evaluation tests (than the 
ones used in most of the studies until now), using operation of the pump at the lowest 
possible rates in terms of safety, need to be tested in future studies. 
• Histological, cellular and molecular indices of genuine recovery (as opposed to simple 
markers of unloading) are the subject of intense research and are expected to greatly 
contribute to the accurate diagnosis of significant ventricular recovery during 
mechanical support (Drakos et al., 2007). 
LVADs designed specifically for recovery (easily implantable and explantable, atraumatic to 
the myocardium, operating in coordination with the native heart) are currently under 
development and may find a place in clinical practice in the future (Nanas et al., 1996). The 
principal of counterpulsation appears particularly promising for this purpose, since the LV 
can be very effectively unloaded, while at the same time it maintains adequate function for 
atrophy to be prevented. In addition, using different levels of support (every cardiac cycle, 
or 1-2, 1-3 etc) cardiac function can be easily assessed and monitored. Implantable 
www.intechopen.com
 
Evaluation of Cardiac Function after VAD Implantation 
 
59 
counterpulsation devices may be used in carefully selected candidates for recovery; if there 
is successful outcome, they can easily be removed, otherwise, they can serve as bridge to a 
permanent device implantation or transplantation. 
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